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(6-(cyclohexylamino)-1,3-dimethyl-5(2-pyridyl)furo[2,3-d]pyrimidine-2,4(1H,3H)-dione) abbreviated as CDP was synthesized
and characterized. Ti(IV), Zn(II), Fe(III), and Pd(II) metal complexes of this ligand are prepared by the reaction of salts of Ti(IV),
Zn(II), Fe(III), and Pd(II) with CDP in acetonitrile. Characterization of the ligand and its complexes was made by microanalyses,
FT-IR, 1H NMR, 13C NMR, and UV-Visible spectroscopy. All complexes were characterized by several techniques using elemental
analysis (C, H, N), FT-IR, electronic spectra, and molar conductance measurements. The elemental analysis data suggest the
stoichiometry to be 1:1 [M:L] ratio formation. The molar conductance measurements reveal the presence of 1:1 electrolytic nature
complexes. These new complexes showed excellent antitumor activity against two kinds of cancer cells that are K562 (human
chronic myeloid leukemia) cells and Jurkat (human T lymphocyte carcinoma) cells.
Copyright © 2008 Fahmideh Shabani et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Nitrogen-containing ligands such as Schiﬀ bases and their
metal complexes played an important role in the devel-
opment of coordination chemistry, resulting in an enor-
mous number of publications, ranging from pure synthetic
work to physicochemical [1] and biochemically relevant
studies of metal complexes [2–6]a n df o u n dw i d er a n g eo f
applications. Other kinds of nitrogen-containing ligands are
well-known pyrimidine systems such as purine analogues
that exhibit a wide range of biological activities. Fused
pyrimidine compounds are valued not only for their rich
and varied chemistry, but also for many important bio-
logical properties. Among them, the furopyrimidine ring
system, because of a formal isoelectronic relationship with
purine, is of special biological interest. It has numerous
pharmacological and agrochemical applications, namely,
antimalarials, antifolates, and antivirus, as well as potential
radiation protection agents. Recently, some furopyrimidines
were shown to be potent vascular endothelial growth
factor receptor2 (VEGFR2) and epidermal growth factor
receptor (EGFR) inhibitors. Because of the importance of
furo[2,3-d]pyrimidinederivatives,severalmethodologiesfor
synthesizing them have already been developed. However,
many of the synthetic protocols reported so far prolonged
reaction times, harsh reaction suﬀer from disadvantages,
such as relying on multistep reactions, needing anhydrous
conditions, low yields, use of metal-containing reagents,
and special instruments or starting materials. Therefore, the
development of new and eﬃcient methods for the prepa-
ration of furo[2,3-d]pyrimidine derivatives is still strongly
desirable [7].2 Bioinorganic Chemistry and Applications
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Figure 1: Synthesis route of CDP ligand.
Pyrimidines represent a very interesting class of com-
pounds because of their wide applications in pharmaceu-
tical, phytosanitary, analytical, and industrial aspects, for
example, as antibacterial, fungicide [8], anti-inﬂammatory,
antihelmintics, antitubercular, anti-HIV, antidegenerative
and hypothermic activities [8], and herbicides [9], and have
biological activities [10–14].
It has long been known that metal ions involve in
biological processes of life and have been subject of interest.
The modes of action of these metal ions are often complex
but are believed to involve bonding to the heteroatoms of
the heterocyclic residues of biological molecules, that is,
proteins, enzymes, nucleic acids, and so forth [15].
From these points of view, it is interesting to study diﬀer-
ent types of transition metal complexes of these biologically
active ligands. In this paper, the synthesis, characterization,
and antitumor properties of a number of the ﬁrst row
transition metal complexes with one of the above ligands
have been studied.
2. MATERIALS AND METHODS
2.1. Chemicalsandreagents
N,N
 -dimethylbarbituricacid,2-pyridinecarbaldehyde,tita-
nium(VI) tetra ﬂuoride, zinc(II) acetate dihydrate, iron(III)
chloride hexahydrate, and palladium chlorides were Merck
chemicals (Darmstadt, Germany) and were used without
further puriﬁcation. Organic solvents were reagent grade.
Electronic spectra were recorded by Camspec UV-Visible
spectrophotometer model Wpa bio Wave S2 100. The IR
spectra were recorded using FT-IR Bruker Tensor 27 spec-
trometer. 1H-NMRand 13C-NMRwererecordedonaBruker
AVANCE DRX 500 spectrometer. All the chemical shifts are
quotedinppmusingthehigh-frequencypositiveconvention;
1Ha n d13C-NMR spectra were referenced to external SiMe4.
The percent composition of elements was obtained from
the Microanalytical Laboratories, Department of Chemistry,
OIRC, Tehran.
2.2. Cellculture
The human chronic myeloid leukemia—K562 cell line—
and the human T lymphocyte carcinoma-Jurkat cell line,
used for treatment with the drugs, were provided. K562 and
Jurkat cells were grown at 37
◦Ci na na t m o s p h e r ec o n t a i n -
ing 5% CO2, with RPMI-1640 Medium HEPES Modiﬁca-
tion with L-glutamine and 25mM HEPES (Sigma-Aldrich
Chemie GmbH, Germany) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Gibco, Carlsbad, Calif,
USA), 2.7% sodium bicarbonate, and 500mg/L ampicillin.
3. EXPERIMENTAL
3.1. SynthesisoftheCDPligand
To a solution of N,N
 -dimethylbarbituric acid (0.78g,
5.0mmol) and 2-pyridinecarbaldehyde (0.54g, 5.0mmol) in
DMF (3mL) in a screw-capped vial was added cyclohexyl
isocyanide (0.55g, 5.0mmol) via a syringe and was shaken
for 1 minute. The reaction mixture was then kept for about
3 0m i n u t e sa tr o o mt e m p e r a t u r e( 2 5
◦C) and the completion
of reaction was conﬁrmed by TLC (EtOAc-hexane 1:2).
Then, the resulting crystals were ﬁltered and washed with
diethyl ether (20mL) to yield as light pink crystals (1.42g,
80%). The dried product thus obtained showed a single spot
on TLC and was pure enough for all analytical purposes [7]
(see Figure 1).
3.1.1. AnalysisofCDPligand
Yield,80%.Mp135.2–137.5
◦C;Anal.Calcd.C19H21N4O3:C,
64.58; H, 5.94; N, 15.86. Found: C, 64.92; H, 6.29; N, 16.08.
1HN M R( C D C l 3): 4.40(1H, d, NH), 8.40 and 7.60(1H,
d, pyridine), 7.55 and 7.26(1H, d, pyridine), 3.61(3H,
s, NCH3), 3.45(3H, s, NCH3), 1.38(2H, m, cyclohexan),
1.63(2H, m, cyclohexan), 2.01(1H, m, cyclohexan); 13C
NMR (CDCl3): 158.63(C4), 154.51(NCON), 153.42(C2),
136.27(C6), 122.3(C3), 149.9, 149.4, 147.2, and 118.4(pyri-
dine), 52.34, 33.92, and 24.49(cyclohexan). IR (KBr, cm−1):
3276w, 1664w, 1593w, 1449m, 1266w, 1120w, 610, and
742s. UV-vis (MeCN): λmax260nm (ε120), 336nm (ε110).
3.2. Synthesisofthemetalcomplexes:
generalmethod
A solution of metal salt dissolved in acetonitrile was added
gradually to a stirred acetonitrile solution of the ligand
(CDP), in the molar ratio 1:1 (metal:ligand). The reaction
mixture was further stirred for 2–4 hours to ensure the
completion and precipitation of the formed complexes.Fahmideh Shabani et al. 3
The precipitated solid complexes were ﬁltered and washed
several times with 50% (v/v) ethanol/water to remove
any traces of the unreacted starting materials. Finally, the
complexes were washed with diethyl ether and dried in
vacuum desiccators over anhydrous CaCl2.
3.2.1. AnalysisofTi(C19H20N4O3)F4
Yield, 85%. Anal. Calcd. Ti(C19H20N4O3)F4: C, 47.89; H,
4.20; N, 11.76. Found: C, 48.2; H, 4.37; N, 12.1. 1HN M R
(DMSO): 9(1H, d, pyridine), 8.30(1H, d, pyridine), 7.1(1H,
d, pyridine), 3.53(3H, s, NCH3), 3.01(3H, s, NCH3), 1.08–
2.5(2H and 1H, m, cyclohexan); IR (KBr, cm−1): 1689s,
1625m, 1453m, 1246w, 1153w, 774s, 667w, and 603s. UV-
vis (MeCN): λmax377nm (ε54), 497nm (ε28).
3.2.2. AnalysisofZn(C19H20N4O3)(OAC)2
Yield, 60%. Anal. Calcd. Zn(C19H20N4O3)(OAC)2: C, 42.57;
H, 3.73; N, 10.45. Found: C, 43.5; H, 3.86; N, 10.82. 1H
NMR (DMSO): 8.30(1H, d, pyridine), 8.06(1H, d, pyridine),
7.5(1H,d,pyridine),3.3(3H,s,NCH3),3(3H,s,NCH3),1.2–
2.35(2H and 1H, m, cyclohexan); IR (KBr, cm−1): 1691s,
1625m,1439w, 1246w, 1158w, and 425s. UV-vis (MeCN):
λmax262nm (ε110), 302nm (ε100), 344nm (ε78), and
415nm (ε60).
3.2.3. AnalysisofFe(C19H20N4O3)Cl3
Yield, 75%. Anal. Calcd. Fe(C19H20N4O3)Cl3: C, 44.32; H,
3.88; N, 10.88. Found: C, 44.86; H, 4.18; N, 11.38. 1H
NMR (DMSO): 9.67(1H, d, pyridine), 9.02(1H, d, pyridine),
7.95(1H, d, pyridine), 3.7(3H, s, NCH3), 3.1(3H, s, NCH3),
1.5–2.8(2H and 1H, m, cyclohexan); IR (KBr, cm−1): 1600w,
1546w, 1444w, 1154s, 514m, and 599s. UV-vis (MeCN):
λmax257nm (ε280), 314nm (ε156), 363nm (ε126), 440nm
(ε60), and 494nm (ε28).
3.2.4. AnalysisofPd(C19H20N4O3)Cl2
Yield, 88%. Anal. Calcd. Fe(C19H20N4O3)Cl3: C, 43.07; H,
3.77; N, 10.57. Found: C, 43.45; H, 3.95; N, 10.89. 1H
NMR (DMSO): 8.31(1H, d, pyridine), 7.55(1H, d, pyridine),
7.37(1H, d, pyridine), 2.55(3H, s, NCH3), 2.5(3H, s, NCH3),
1.18–2.07(2H and 1H, m, cyclohexan); IR (KBr, cm−1):
1649s, 1546m, 1467m, 1266m, 1142m, and 495m. UV-
vis (MeCN): λmax261nm (ε220), 307 nm (ε130), 442nm
(ε118), and 660nm (ε75).
3.3. Cytotoxicitystudies
CDP ligand and Ti(C19H20N4O3)F4,Z n ( C 19H20N4O3)
(OAC)2,F e ( C 19H20N4O3)Cl3,a n dP d ( C 19H20N4O3)Cl2
complexes areﬁve compounds which were assayed for
cytotoxicity in vitro against K562 (human chronic myeloid
leukemia)cellsandJurkat(humanTlymphocytecarcinoma)
cells.
The two cell lines were provided by the Pasteur Institute
in Iran. The procedure for cytotoxicity studies was similar
(a)
(b)
Figure 2: (a) Tumor cell after 72h without Pd(C19H20N4O3)Cl2
compound. (b) tumor cell after 72h with Pd(C19H20N4O3)Cl2
compound.
to that reported earlier [16]. Brieﬂy, in order to calculate
the concentration of each drug that produces a 50%
inhibition of cell growth (IC50), 190mL of cell suspension
4 ×105 cell/mL) was exposed to various concentrations of
ligand and complexes dissolved in sterile DMSO. The ﬁnal
concentrationofDMSOinthegrowthmediumwas2%(v/v)
or lower, concentrations without eﬀect on cell replication
[17, 18].
After the incubation periods 72 hours for all cell lines,
the cell concentrations were determined both in control and
in drug-treated cultures. All experiments were done for six
times (see Figure 2).
4. RESULTS AND DISCUSSION
4.1. Preparationforligand,CDP,andTi(IV),Zn(II),
Fe(III),andPd(II)complexes
The reaction of Ti(IV), Zn(II), Fe(III), and Pd(II) salts with
the ligand, CDP, results in the formation of [ML]for M =
Ti(IV), Zn(II), Fe(III), and Pd(II). All complexes are quite
stable and could be stored without any appreciable change.
All complexes were characterized by several techniques using
elemental analyze (C, H, N), FT-IR, electronic spectra, and
molar conductance measurements. The elemental analysis
data suggest the stoichiometry to be 1:1 [M:L]ratio for-
mation. The molar conductance measurements reveal the
presence of 1:1 electrolytic nature complexes. The com-
plexes Ti(C19H20N4O3)F4,Z n ( C 19H20N4O3)(OAC)2,a n d
Pd(C19H20N4O3)Cl2 do not have sharp melting points but
decompose above 237
◦C, 290
◦C, and 331
◦C, respectively,
but Fe(C19H20N4O3)Cl3 complex has 153
◦C–155
◦C melting
point. They are insoluble in common organic solvents,4 Bioinorganic Chemistry and Applications
Table 1: 72-hour IC50 and IC90 values (μM) obtained for CDP and
three CDP complexes.
Complexes IC50 for cell line IC90 for cell line
K562 Jurkat K562 Jurkat
CDP >110 >110 — —
Ti(C19H20N4O3)F4 >70 >50 >100 >100
Zn(C19H20N4O3)(OAC)2 >100 >100 >150 >150
Fe(C19H20N4O3)Cl3 >45 >40 >120 >120
Pd(C19H20N4O3)Cl2 >36 >33 >85 >80
such as ethanol, methanol, chloroform, or acetone; however,
they are soluble in DMSO and DMF. Their structures were
characterized by elemental analysis, 1HNMR and IR. Their
elementalanalysesareinaccordwiththeirproposedformula.
The spectral data of the complexes have good relationship
with the literature data.
4.2. Cytotoxicityassaysinvitro
CDP ligand and Ti(C19H20N4O3)F4,Z n ( C 19H20N4O3)
(OAC)2,F e ( C 19H20N4O3)Cl3,a n dP d ( C 19H20N4O3)Cl2
c o m p l e x e sh a v eb e e nt e s t e da g a i n s tt w oh u m a nc a n c e rc e l l
lines: K562 and Jurkat. The IC50 cytotoxicity values of the
complexes were compared to those found for the starting
organic bases as well as for some of the anticancer agents
used nowadays, that are cisplatin and oxaplatin compounds
[19].
The general method used for testing on antitumor prop-
ertiesofthesecompoundsisthestandardtestingmethodthat
has been previously described in greater detail.
After preincubation lasting for 12 hours at 37
◦C
in a 5% CO2 atmosphere and 100% humidity, the
tested compounds in the concentration ranges of 0.1–
250μM for CDP, of 0.1–150μMf o rT i ( C 19H20N4O3)F4,
of 0.1–100μMf o rZ n ( C 19H20N4O3)(OAC)2,o f0 . 1 –
200μMf o rF e ( C 19H20N4O3)Cl3, and of 0.1–97μMf o r
Pd(C19H20N4O3)Cl2 were added. The incubation lasted
for 72 hours and at the end of this period IC90 and IC50
of the dead cells and live cells were measured by trypan
blue. The mechanism by which these complexes act as
antitumor agents is apoptosis. IC90 and IC50 values that
are the compounds concentrations lethal for 90% and 50%
of the tumor cells were determined both in control and in
compounds concentrations lethal for both in compounds-
treated cultures. The compounds were ﬁrst dissolved in
DMSO and then ﬁltrated. The corresponding 50% and
90% inhibitory doses (IC50 and IC90) values are shown in
Table 1.
5. CONCLUSION
It is clear from the above discussion that Ti(IV), Zn(II),
Fe(III) and Pd(II) complexes and CDP ligand oﬀer a new
outlook for chemotherapy. The results of antitumor activity
show that the metal complexes exhibit antitumor properties
and it is important to note that they show enhanced
inhibitory activity comparedtothe parent ligand. The mech-
anism by which these complexes act as antitumor agents is
apoptosis. It has also been proposed that concentration plays
a vital role in increasing the degree of inhabitation.
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